Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
Agios Pharmaceuticals announced new detailed data presentations of mitapivat at the 31st European Hematology Association Congress (EHA 2026). Results from the pivotal RISE UP Phase 3 trial in sickle cell disease demonstrate significant hemoglobin improvements and anti-hemolytic effects. Additional positive long-term data from ENERGIZE trials in tha…